Clinical Trial Detail

NCT ID NCT03441061
Title Study of Inotuzumab Ozogamicin in Patients With B-cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors M.D. Anderson Cancer Center
Indications

B-cell adult acute lymphocytic leukemia

Therapies

inotuzumab ozogamicin

Age Groups: adult senior

Additional content available in CKB BOOST